SAN DIEGO--(BUSINESS WIRE)--
Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and
manufacturer of the only touchscreen insulin pumps available in the
United States, today announced that it is proposing to offer and sell
shares of its common stock, Series A warrants and Series B warrants to
purchase shares of its common stock in an underwritten public offering.
All of the shares of common stock and warrants to be sold in the
offering are being offered by Tandem. The offering is subject to market
conditions and there can be no assurance as to whether or when the
offering may be completed, or as to the actual size or terms of the
offering. The Company intends to use the net proceeds from the proposed
offering for working capital and other general corporate purposes.
Oppenheimer & Co. Inc. is acting as the sole book‐running manager for
the offering. National Securities Corporation, a wholly owned subsidiary
of National Holdings Corporation (NasdaqCM: NHLD), is acting as a
co-manager in connection with the offering.
This offering is being made pursuant to a shelf registration statement
on Form S-3 that was previously filed by Tandem with the Securities and
Exchange Commission and declared effective on December 19, 2014. A
preliminary prospectus supplement and accompanying prospectus describing
the terms of the proposed offering will be filed with the Securities and
Exchange Commission and will form a part of the effective registration
statement. When available, copies of the preliminary prospectus
supplement and the accompanying prospectus relating to the securities
being offered may be obtained from: Oppenheimer & Co. Inc. Attention:
Syndicate Prospectus Department, 85 Broad St., 26th Floor,
New York, NY 10004, by telephone at (212) 667-8563 or by email at EquityProspectus@opco.com.
Electronic copies of the preliminary prospectus supplement and
accompanying prospectus will also be available on the Securities and
Exchange Commission's website at www.sec.gov.
This press release does not constitute an offer to sell or the
solicitation of an offer to buy any of the securities described herein,
nor shall there be any sale of these securities in any state or
jurisdiction in which such offer, solicitation or sale would be unlawful
prior to registration or qualification under the securities laws of any
such state or jurisdiction. The offering will be made only by means of a
prospectus that forms a part of the registration statement.
About Tandem Diabetes Care, Inc.
Tandem Diabetes Care, Inc. (www.tandemdiabetes.com)
is a medical device company dedicated to improving the lives of people
with diabetes through relentless innovation and revolutionary customer
experience. The Company takes an innovative, user-centric approach to
the design, development and commercialization of products for people
with diabetes who use insulin. Tandem manufactures and sells the t:slim
X2™ Insulin Pump, the only pump capable of remote feature updates using
a personal computer, now available with Dexcom G5® Mobile continuous
glucose monitoring (CGM) integration, and the t:flex® Insulin Pump, the
first pump designed for people with greater insulin requirements. Tandem
is based in San Diego, California.
Follow Tandem Diabetes Care on Facebook at www.facebook.com/TandemDiabetes.
Tandem Diabetes Care on LinkedIn at https://www.linkedin.com/company/tandemdiabetes.
t:flex and Tandem Diabetes Care are registered trademarks, and t:slim X2
is a trademark of Tandem Diabetes Care, Inc. Dexcom G5 is a registered
trademark of Dexcom, Inc.
Forward Looking Statements
This press release contains "forward-looking statements" within the
meaning of Section 27A of the Securities Act of 1933, as amended, and
Section 21E of the Securities Exchange Act of 1934, as amended, that
concern matters that involve risks and uncertainties that could cause
actual results to differ materially from those anticipated or projected
in the forward-looking statements. These forward-looking statements
include statements regarding the Company's expectations regarding the
sales of shares and warrants in the proposed offering and other
statements that are not purely statements of historical fact. Such
forward-looking statements are based on the Company's current
expectations and involve assumptions that may never materialize or may
prove to be incorrect. Actual results, and the timing of events, may
differ materially from those indicated by such forward-looking
statements as a result of various important factors, including the
uncertainties regarding market conditions and the completion of the
underwritten offering on the anticipated terms or at all. Other risks
and uncertainties are identified in the Company's most recent Annual
Report on Form 10-K and Quarterly Report on Form 10-Q, and other
documents that the Company files with the Securities and Exchange
Commission including the Registration Statement on Form S-3 (File No.
333-200686) for the offering. Investors are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of the
date of this release. Unless otherwise required by applicable law or the
rules of the NASDAQ Stock Market, Tandem undertakes no obligation to
update or revise any forward-looking statement in this press release
because of new information, future events or other factors.
View source version on businesswire.com: http://www.businesswire.com/news/home/20171012006394/en/
for Tandem Diabetes Care
Source: Tandem Diabetes Care, Inc.
News Provided by Acquire Media